ClinicalTrials.gg
Active, not recruitingNCT04126200DREAMM 5Updated May 6, 2026Results posted

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 1/2 interventional study of Belantamab mafodotin and GSK3174998 in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 38 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Multiple Myeloma by GlaxoSmithKline — 6 open to participants now, 20 under way, 7 of them phase 3. Multiple Myeloma · GlaxoSmithKline.

Enrollment
7th of 40
208 · median 41
Started
2019
with 6 others
Phase 1/2
11 of 42
1 open now
Primary completion
2025-04
later than 6 of 19 live
Registered
18th of 42
by date

Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 7th largest by enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2019, is one of 11 in phase 1/2, reaches primary completion later than 6 of the 19 other live ones, and was the 18th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 42 studies in Multiple Myeloma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Multiple Myeloma by GlaxoSmithKline, or all of them as a file.
02

Study summary

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Belantamab mafodotin
  • GSK2857916
  • GSK3174998
  • Feladilimab
  • Nirogacestat
  • Dostarlimab
  • Isatuximab
  • Lenalidomide
  • Dexamethasone
  • Pomalidomide
  • Platform study
  • Relapsed/Refractory Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Participant must be 18 years of age inclusive or older, at the time of signing the .

  • Participants must have or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the IMWG.
  • Participants having at least 3 prior lines of prior anti-myeloma treatments including an immunomodulating agent (IMID) a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.
  • Participants with a history of stem cell transplant are eligible for study participation when, transplant was >100 days prior to study enrolment and with no active infection(s).
  • Participants with (ECOG) performance status of 0-1, unless ECOG less than equal to (\<=)2 is due solely to skeletal complications and/or skeletal pain due to MM.
  • Participants with defined as at least one of the following: Serum M-protein greater than equal to (>=)0.5 gram per deciliter (>=5 gram per liter) or Urine M-protein >=200 mg per 24 hours or Serum free light chain (FLC) assay: Involved FLC level >=10 mg per deciliter (>=100 mg per Liter) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  • Participants who have tested positive for core antibody (HBcAb) can be enrolled if the following criteria are met: Serology result HBcAb+, Hepatitis B surface antigen (HBsAg)-; HBV DNA undetectable during screening.
  • Participants who are currently receiving physiological doses oral (\<10 mg/day), inhaled steroids or ophthalmalogical steroids.

Inclusion Criteria Specific to Sub-study 6 and7:

  • Participants with requirements specific to Sub-study 6 and 7 respectively.
  • Participants with value for Adequate Organ System Function is ≥75 × 10\^9/L.

Exclusion Criteria:

  • Participants with current corneal epithelial disease except mild punctate keratopathy.
  • Participants with evidence of cardiovascular risk
  • Participants with known immediate or delayed reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other mAb.
  • Participants with active infection requiring antibiotic, antiviral, or antifungal treatment.
  • Participants with other monoclonal antibodies within 30 days or systemic anti-myeloma therapy within \<14 days.
  • Participants with prior radiotherapy within 2 weeks of start of study therapy.
  • Participants with prior allogeneic transplant are prohibited.
  • Participants who have received prior Chimeric Antigen T cell therapy (CAR-T) therapy with lymphodepletion with chemotherapy within 3 months of screening.
  • Participants with any major surgery (other than bone-stabilizing surgery) within the last 30 days.
  • Participants with prior treatment with an agent within 14 days or 5 half-lives of receiving the first dose of study drugs, whichever is shorter.
  • Participants with >=grade 3 toxicity considered related to prior check-point inhibitors and that led to treatment discontinuation.
  • Participants who have received transfusion of blood products within 2 weeks before the first dose of study drug.
  • Participants must not receive within 30 days prior to first dose of study treatment or whilst receiving belantamab mafodotin +- partner agent in any sub-study arm of the platform trial and for at least 70 days following last study treatment.
  • Participants with presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM.
  • Participants with Known infection, unless the participant can meet all criteria: a) established anti-retroviral therapy for at least 4 weeks and HIV viral load\<400 copies/mL b) CD4+ T-cell (CD4+) counts >= 350 cells/microliter (µL) c) No history of AIDS-defining opportunistic infections within the last 12 months in which case the participant would be eligible for CE Phase only.

For patients receiving nirogacestat, HIV drugs that are strong inhibitors are prohibited. HIV drugs that are moderate CYP3A4 inhibitors, while permitted, should be co-administered with caution and must be accompanied by nirogacestat dose modifications.

Additional Exclusion Criteria for Sub-study 1 and Sub-study 2:

  • Participants with disease (current or history) or syndrome that required systemic treatment within the past 2 years.
  • Exclusion for a recent (within the past 6 months) history of symptomatic pericarditis.

Additional Exclusion Criteria for Sub-study 3, 6 and 7:

  • Participants with uncontrolled small and/or large intestinal disease.
  • Participants with uncontrolled skin disease.
  • Participants with any condition causing hypophosphatemia, hypokalemia or hypomagnesemia which is to electrolyte replacement.
  • Participants with previous administration of a gamma secretase inhibitor.
  • Participants with concomitant administration of a strong CYP3A4 inhibitor or inducer.

Additional Exclusion Criteria for Sub-study 4:

  • Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, corticosteroids, or drugs).
  • Participants who have received prior therapy with an anti-programmed death-1 (), anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed.

Additional Exclusion Criteria for Sub-study 5:

  • Participants with Severe hypersensitivity to Isatuximab-irfc or to any of its .
  • Participants with prior treatment with other anti-CD38 monoclonal antibody within 6 months of the first dose of study drug treatment.
  • Participants with known intolerance or hypersensitivity to infused proteins products, sucrose, histidine, and polysorbate 80.

Additional Exclusion Criteria for Sub-study 6 and 7:

  • Participants with active or history of venous thromboembolism within the past 3 months.
  • Participants with evidence of active mucosal or internal bleeding
  • Participants with to or are unwilling to undergo protocol-required anti-thrombotic prophylaxis or unable to tolerate antithrombolitic prophalaxis,

Additional Exclusion Criteria for Sub-study 6:

- Participants who discontinued prior treatment with lenalidomide due to intolerable adverse events

Additional Exclusion Criteria for Sub-study 7:

- Participants who discontinued prior treatment with pomalidomide due to intolerable adverse events

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1)

    Drug: Belantamab mafodotin · Drug: GSK3174998

  • Experimental
    Belantamab mafodotin+feladilimab dose exploration (Sub-study 2)

    Drug: Belantamab mafodotin · Drug: Feladilimab

  • Experimental
    Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3)

    Drug: Belantamab mafodotin · Drug: Nirogacestat

  • Experimental
    Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4)

    Drug: Belantamab mafodotin · Drug: Dostarlimab

  • Experimental
    Belantamab mafodotin+isatuximab dose exploration (Sub-study 5)

    Drug: Belantamab mafodotin · Drug: Isatuximab

  • Experimental
    Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6)

    Drug: Belantamab mafodotin · Drug: Nirogacestat · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7)

    Drug: Belantamab mafodotin · Drug: Nirogacestat · Drug: Dexamethasone · Drug: Pomalidomide

  • Active comparator
    Belantamab mafodotin monotherapy cohort expansion

    Drug: Belantamab mafodotin

  • Experimental
    Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1)

    Drug: Belantamab mafodotin · Drug: GSK3174998

  • Experimental
    Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2)

    Drug: Belantamab mafodotin · Drug: Feladilimab

  • Experimental
    Belantamab mafodotin+ nirogacestat cohort expansion (Sub-study 3)

    Drug: Belantamab mafodotin · Drug: Nirogacestat

  • Experimental
    Belantamab mafodotin+ dostarlimab cohort expansion (Sub-study 4)

    Drug: Belantamab mafodotin · Drug: Dostarlimab

  • Experimental
    Belantamab mafodotin+ isatuximab cohort expansion (Sub-study 5)

    Drug: Belantamab mafodotin · Drug: Isatuximab

  • Experimental
    Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6)

    Drug: Belantamab mafodotin · Drug: Nirogacestat · Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7)

    Drug: Belantamab mafodotin · Drug: Nirogacestat · Drug: Dexamethasone · Drug: Pomalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Randomized Across Sub-studies

    Number of Participants who passed screening and were randomized across sub studies are presented.

    Time frame: Day 1

07

Results

Posted May 6, 2026

Participant flow

This master record includes data of screened participants for its sub-studies, 208887 Substudy 1 (NCT06160609), Substudy 2 (NCT07217119), Substudy 3 (NCT07084896), Substudy 4 (NCT06655818), Substudy 5 (NCT07217184), Substudy 6 (NCT07150091), Substudy 7 (NCT07150104) and only contains data collected during screening phase (Day -30 to Day 0). Results are presented separately for each sub study.

Participant flow — Overall Study
MilestoneAll Screened Participants
Started271
Completed208
Not completed63
Withdrew: Screen failed62
Withdrew: Completed screening but not randomized to sub study1

Outcome measures

PrimaryNumber of Participants Randomized Across Sub-studies

Number of Participants who passed screening and were randomized across sub studies are presented.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants Randomized Across Sub-studies
ParticipantsAll Screened Participants
Substudy 19
Substudy 225
Substudy 3106
Substudy 44
Substudy 530
Substudy 620
Substudy 714

Adverse events

Collected over Adverse events were not monitored/assessed during the screening phase (Day -30 to Day 0).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Screened Participants———

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)All Screened Participants
Mean67.1 ± 8.89
Sex: Female, Male
Sex: Female, Male(Participants)All Screened Participants
Female122
Male149
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Screened Participants
Asian46
White209
All Other Races12
Missing4
08

Study locations

38 sites
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Grand Rapids, Michigan 49546, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
  • GSK Investigational Site
    Porto Alegre, 90110-270, Brazil
  • GSK Investigational Site
    Salvador, 41253-190, Brazil
  • GSK Investigational Site
    São Paulo, 04537-080, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V5Z1M9, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Lille, 59037, France
  • GSK Investigational Site
    Villejuif, 94805, France
  • GSK Investigational Site
    Frankfurt, 60590, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Kiel, 24105, Germany
  • GSK Investigational Site
    Leipzig, 04103, Germany
  • GSK Investigational Site
    Athens, 11528, Greece
  • GSK Investigational Site
    Mexico City, 01330, Mexico
  • GSK Investigational Site
    Leeuwarden, 8934 AD, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 CX, Netherlands
  • GSK Investigational Site
    Oslo, 0450, Norway
  • GSK Investigational Site
    Gdansk, 80-214, Poland
  • GSK Investigational Site
    Katowice, 40-519, Poland
  • GSK Investigational Site
    Lodz, 93-513, Poland
  • GSK Investigational Site
    Lublin, 20-081, Poland
  • GSK Investigational Site
    Incheon, 21565, South Korea
  • GSK Investigational Site
    Seoul, 03080, South Korea
  • GSK Investigational Site
    Seoul, 06351, South Korea
  • GSK Investigational Site
    Seoul, 06591, South Korea
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Madrid, 28027, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    PamplonaNavarra, 31008, Spain
  • GSK Investigational Site
    Pozuelo de AlarcOn Madr, 28223, Spain
  • GSK Investigational Site
    Falun, SE-791 82, Sweden
  • GSK Investigational Site
    Stockholm, SE-141 86, Sweden
09

References and documents

Publications

  • Hosoya H, Sidana S. Antibody-Based Treatment Approaches in Multiple Myeloma. Curr Hematol Malig Rep. 2021 Apr;16(2):183-191. doi: 10.1007/s11899-021-00624-6. Epub 2021 Mar 17. PubMed 33730360 ↗
  • Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, Quach H, Callander N, Minnema MC, Trudel S, Jackson NA, Ahlers CM, Im E, Cheng S, Smith L, Hareth N, Ferron-Brady G, Brouch M, Montes de Oca R, Paul S, Holkova B, Gupta I, Kremer BE, Richardson P. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021 Jun;17(16):1987-2003. doi: 10.2217/fon-2020-1269. Epub 2021 Mar 8. PubMed 33682447 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Apr 2025, 66 months.

Results were first posted in May 2026, 1 year after primary completion.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 66 months is close to that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 15, 2019
StartActual
Oct 7, 2019
Primary completionActual
Apr 17, 2025
CompletionEst.
Mar 11, 2027
Results first posted
May 6, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04126200
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 15, 2019
Start date
Oct 7, 2019
Primary completion
Apr 17, 2025
Completion
Mar 11, 2027 (estimated)
Results posted
May 6, 2026
Last update
May 6, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion